The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2024 | Ezabenlimab + mDFC + CRT in stage III anal carcinoma: INTERACT-ION study early results
Stefano Kim, MD, Centre Hospitalier Universitaire de Besançon, Besançon, France, presents the ongoing Phase II study INTERACT-ION (NCT04719988). The study focuses on patients with treatment-naïve Stage III (T4N0 or TxN+) squamous cell carcinoma of the anus (SCCA). The trial evaluates the combination of ezabenlimab (anti-PD-1 antibody) with modified dose-dense fluorouracil, cisplatin, and docetaxel (mDCF) as induction therapy, followed by chemoradiotherapy (CRT) and maintenance with ezabenlimab. Preliminary results, based on 37 evaluated patients, show that 97% received the planned induction treatment, and 97% demonstrated radiological objective response, with 42.4% achieving a complete response. The study indicates promising antitumor activity and manageable safety for this novel treatment approach in locally advanced SCCA. Further evaluation and exploration of this treatment regimen are warranted. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
